A Study of PM1015 in Patients With Advanced Solid Tumors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
PM1015 is a specific antibody targeting CD73. This is a phase I study to evaluate the efficacy and safety of PM1015 in patients with advanced solid tumor.
Epistemonikos ID: 215aac663d8691ba89a16378d476d44794c7fcc7
First added on: May 15, 2024